Lisocabtagene Maraleucel for Richter's Transformation-A Case Series

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Richter's transformation (RT) is a high-risk progression of chronic lymphocytic leukemia (CLL) to lymphoma.
• Effective treatment options for RT remain limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) in patients with RT.
• To assess the impact of concurrent ibrutinib therapy on treatment outcomes in RT.

Main Methods:

• A single-institution case series included six patients with RT who received liso-cel.
• Data collected included efficacy, safety, CAR-T expansion, and measurable residual disease (MRD).

Main Results:

• An overall response rate of 83.3% was observed.
• Four patients receiving concurrent ibrutinib maintained MRD-negative complete responses.
• No severe (grade 3+) cytokine release syndrome occurred; one patient experienced severe (grade 3+) ICANS.

Conclusions:

• Lisocabtagene maraleucel (liso-cel) combined with concurrent ibrutinib may represent a promising therapeutic strategy for RT.
• Further investigation is warranted to confirm these findings in larger studies.